Joint Pain Treatment in Birmingham & Bessemer, AL

Joint Pain Treatment at Alabama Pain Physicians

Whether it's your knee, hip, shoulder, or ankle — joint pain limits your life. Our board-certified physicians treat joint pain every day using a combination of medical management and minimally invasive procedures.

Your treatment plan may include:

• Medical management — anti-inflammatories, topical pain medications, and disease-specific treatments
• Joint injections — corticosteroid injections to reduce inflammation and pain directly in the affected joint
• Viscosupplementation — hyaluronic acid injections (gel shots) for knee osteoarthritis
• Genicular nerve blocks and RF ablation — for chronic knee pain, providing months of relief without surgery
• SI joint injections and RF ablation — for sacroiliac joint dysfunction causing hip and low back pain
• Peripheral nerve blocks — targeted treatment for shoulder, hip, and ankle pain
• Medical marijuana certification — for qualifying patients with chronic joint pain and arthritis

Joint pain doesn't always mean surgery. Many patients find significant relief through our non-surgical treatments. We'll evaluate you thoroughly and discuss all your options.

Understanding Joint Pain: A Multi-System Perspective

The following publication by Ty Thomas, MD explores the deeper biological mechanisms behind why joint pain develops and persists. This research informs how we approach complex and treatment-resistant cases at Alabama Pain Physicians.

Author’s Statement

I am a board-certified Physical Medicine and Rehabilitation physician with additional certification in Venous and Lymphatic Medicine. For over fifteen years at Alabama Pain Physicians, I have managed thousands of patients with degenerative joint disease of the knee, hip, and shoulder. The consistent observation that drives this publication series is the limited, partial treatment response that characterizes conventional management of joint pain. A corticosteroid injection into an osteoarthritic knee reduces pain for one to three weeks, then the pain returns. A total knee replacement corrects the end-stage structural damage but does not address the biology that destroyed the cartilage — and patients with unaddressed metabolic dysfunction have worse surgical outcomes. A frozen shoulder in a perimenopausal woman is treated with physical therapy and injections while the hormonal and metabolic environment driving the capsular fibrosis is never evaluated. These partial responses are not clinical failures. They are evidence that the interventions are addressing only one component of a multi-component problem.

This observation led me to cellular systems biology as a framework for understanding joint degeneration. Osteoarthritis is particularly instructive because the prevailing model — mechanical wear and tear — cannot explain why hand osteoarthritis occurs in non-weight-bearing joints of obese patients, why diabetics have two to four times the rate of frozen shoulder, or why nearly half of individuals with diabetes have some form of arthritis. These observations point to a systemic metabolic process, not a local mechanical one. I have spent years developing assessment protocols, building laboratory infrastructure through CLIA-certified laboratories, and studying the biological pathways that connect metabolic, inflammatory, hormonal, and vascular domains to joint health.

These publications are my attempt to provide information about this understanding — how common clinical manifestations of pain can be explained, diagnosed, and treated through cellular systems analysis. They are not a claim to have found a root cause. They are a framework for asking better questions.

Abstract

Background

Osteoarthritis is the most common form of arthritis, affecting over 500 million people worldwide with knee osteoarthritis projected to increase 74.9% by 2050 (GBD 2021, Lancet Rheumatology, 2023). Approximately 303 million cases of hip and knee osteoarthritis were documented in 2017 alone (Safiri et al., Annals of the Rheumatic Diseases, 2020). Adhesive capsulitis affects 2–5% of the general population but 10–20% of diabetics, with three-quarters of patients being female (Bunker and Anthony, Journal of Bone and Joint Surgery, 1995). Current treatment approaches target individual mechanisms: intra-articular corticosteroids reduce pain for one to three weeks with no evidence of sustained functional improvement (Jüni et al., Cochrane Database of Systematic Reviews, 2015), NSAIDs address cyclooxygenase-mediated inflammation with gastrointestinal and cardiovascular risks, and total joint replacement corrects end-stage structural damage without addressing the metabolic environment that produced it. These limited response patterns suggest that single-pathway interventions are insufficient for conditions involving multiple biological systems.

Methods

We conducted a narrative review of PubMed-indexed literature examining joint pain through cellular systems theory, which proposes that osteoarthritis and adhesive capsulitis emerge from dynamic interactions across seven biological domains. We reviewed evidence for metabolic, mitochondrial, inflammatory, neuroendocrine, microbiome, vascular, and structural domain involvement in knee, hip, and shoulder joint disease. We analyzed treatment response data for conventional interventions and constructed composite clinical scenarios illustrating individualized multi-domain assessment and intervention.

Results

Published evidence demonstrates that joint pain involves dysfunction across multiple biological domains: insulin resistance indices are significantly associated with knee osteoarthritis independently of body weight (Korean NHANES analysis, 2025); approximately 47.3% of individuals with diabetes have some form of arthritis; hand osteoarthritis in non-weight-bearing joints of obese patients demonstrates metabolic rather than purely mechanical pathology; adhesive capsulitis is increasingly recognized as a systemic immunometabolic disorder involving estrogen deficiency, thyroid dysfunction, insulin resistance, and endothelial dysfunction rather than an isolated musculoskeletal condition; and high BMI contributes to approximately 20% of osteoarthritis burden through both mechanical and metabolic pathways (GBD 2021).

Conclusions

The pattern of multi-domain biological dysfunction combined with limited, partial response to single-pathway treatments supports the hypothesis that joint pain represents a multi-system cellular disorder requiring individualized, domain-specific intervention. Cellular systems theory provides a framework for identifying which domains are dysfunctional in each patient and directing treatment accordingly.

1. Introduction

Osteoarthritis is the most common form of arthritis and a leading cause of disability worldwide. The Global Burden of Disease Study 2021 documented over 500 million people affected globally, with knee osteoarthritis as the most prevalent site and cases projected to increase 74.9% by 2050 driven by population aging and rising obesity rates (GBD 2021 Osteoarthritis Collaborators, Lancet Rheumatology, 2023). In 2017, approximately 303 million cases of hip and knee osteoarthritis were documented worldwide (Safiri et al., Annals of the Rheumatic Diseases, 2020). For adults aged 70 years and older, osteoarthritis is the seventh ranked cause of years lived with disability. The economic burden is enormous: osteoarthritis drives over one million joint replacement surgeries annually in the United States alone, and metabolic comorbidities adversely impact post-surgical functionality, particularly after hip replacement (Bone Research, 2023).

The prevailing clinical model for osteoarthritis is mechanical-degenerative. Cartilage wears down from age, overuse, injury, and excess weight. Treatment targets the structural damage: anti-inflammatory medications for symptomatic relief, corticosteroid injections to suppress local inflammation, hyaluronic acid injections for lubrication, and ultimately joint replacement when conservative measures fail. This model is logical, evidence-based for symptom management, and effective for end-stage surgical intervention.

However, three clinical observations challenge the sufficiency of this purely mechanical model. First, hand osteoarthritis occurs in non-weight-bearing joints of obese patients, demonstrating that the metabolic consequences of obesity — not just mechanical overloading — drive cartilage degradation. Second, nearly 47.3% of individuals with diabetes have some form of arthritis, a prevalence far exceeding what mechanical factors alone would predict. Third, adhesive capsulitis of the shoulder — frozen shoulder — occurs in 10–20% of diabetics compared with 2–5% of the general population, peaks in perimenopausal women aged 40–60, and is strongly associated with thyroid dysfunction. These patterns point to systemic metabolic, hormonal, and inflammatory processes that converge on joints regardless of mechanical load.

Cellular systems theory proposes that joint degeneration — whether in the knee, hip, or shoulder — emerges from the dynamic interaction of metabolic, inflammatory, hormonal, vascular, and structural domains. The cartilage does not degrade in a biological vacuum. It degrades within a metabolic environment that either supports or undermines chondrocyte survival, extracellular matrix maintenance, and tissue repair. When that biological environment is dysfunctional across multiple domains simultaneously, single-pathway interventions — whether an injection, a pill, or a prosthetic joint — cannot produce sustained improvement because the biological conditions that destroyed the cartilage remain active and will damage the replacement or the adjacent structures.

2. Methods

We conducted a narrative review of PubMed-indexed literature examining biological domain dysfunction in osteoarthritis and adhesive capsulitis. Search terms included osteoarthritis, knee osteoarthritis, hip osteoarthritis, shoulder osteoarthritis, adhesive capsulitis, frozen shoulder combined with insulin resistance, metabolic syndrome, metabolic osteoarthritis, advanced glycation end products, adipokines, leptin, NF-κB, chondrocyte metabolism, subchondral bone, estrogen, perimenopause, thyroid, HPA axis, microbiome, oxidative stress, mitochondrial dysfunction, endothelial dysfunction, and treatment response. We included systematic reviews, meta-analyses, randomized controlled trials, and large population-based cohort studies. We analyzed treatment response data from systematic reviews and meta-analyses of conventional joint pain interventions. We constructed composite clinical scenarios to illustrate individualized multi-domain assessment and intervention.

3. The Limitations of Single-Pathway Treatment

3.1 Intra-Articular Corticosteroid Injections

Intra-articular corticosteroid injections for knee osteoarthritis reduce pain at one to two weeks (NNT 3–4) with moderate benefit, but evidence of benefit diminishes to small effects at four to six weeks and no detectable effect at 26 weeks (Jüni et al., Cochrane Database of Systematic Reviews, 2015). A Cochrane review of 28 trials with 1,973 participants found no evidence that corticosteroid injections improve function beyond the first few weeks. Perhaps most concerning, data from the Osteoarthritis Initiative demonstrated that corticosteroid injections were associated with higher structural progression of knee osteoarthritis on MRI compared with hyaluronic acid injections and controls, suggesting that repeated corticosteroid exposure may accelerate the very pathology it is treating (Radiology, 2024). Corticosteroid injections suppress local inflammation at one joint without addressing the systemic metabolic, inflammatory, and hormonal environment driving cartilage degeneration throughout the body.

3.2 NSAIDs and Analgesics

NSAIDs inhibit cyclooxygenase-mediated prostaglandin synthesis, reducing pain and inflammation. They are the most widely used medications for osteoarthritis worldwide. However, they do not modify disease progression, carry gastrointestinal bleeding risk, cardiovascular risk with chronic use, and renal toxicity. Long-term NSAID use does not prevent the need for joint replacement. More critically, NSAIDs damage the gastrointestinal mucosa, potentially worsening gut barrier function and feeding the systemic inflammatory cascade that contributes to cartilage degradation through adipokine-mediated pathways. Opioids for osteoarthritis pain suppress the HPA axis, reduce testosterone, disrupt sleep, cause weight gain, and impair physical activity — actively worsening the metabolic, hormonal, and deconditioning domains while modulating pain perception.

3.3 Total Joint Replacement

Total joint replacement is highly effective for end-stage osteoarthritis, providing substantial pain relief and functional improvement. It is one of the most successful surgical interventions in medicine. However, it does not address the biological environment that produced the joint degeneration. Metabolic abnormalities adversely impact patient functionality following joint replacement, particularly after hip surgery (Bone Research, 2023). Patients with unaddressed insulin resistance, systemic inflammation, hormonal insufficiency, and obesity have higher complication rates, slower rehabilitation, and inferior long-term outcomes. The demand for joint replacement is projected to increase dramatically as osteoarthritis prevalence rises, but surgery treats one joint at a time while the metabolic environment continues to damage every other joint.

3.4 Frozen Shoulder Treatments

Adhesive capsulitis has no cure. The condition follows a self-limiting but prolonged course of one to three and a half years through freezing, frozen, and thawing phases. Physical therapy is the mainstay of treatment but must be carefully calibrated — aggressive stretching during the freezing phase worsens capsular inflammation. Corticosteroid injections provide temporary pain relief. Hydrodilatation may improve mobility. Surgical manipulation under anesthesia or arthroscopic capsular release is reserved for refractory cases. None of these interventions address the hormonal, metabolic, or endothelial dysfunction increasingly recognized as driving capsular fibrosis. The treatment paradigm focuses on managing a joint condition while ignoring the systemic biology that created it.

3.5 Synthesis: The Pattern of Partial Response

The treatment response data across all conventional modalities for joint pain converge on a consistent pattern: corticosteroid injections provide weeks of relief, NSAIDs manage symptoms without modifying disease, joint replacement corrects end-stage damage without addressing causation, and frozen shoulder treatments manage a condition that takes years to resolve on its own. This is the pattern predicted by a multi-domain disorder being treated with single-domain interventions. If joint degeneration involves variable dysfunction across metabolic, inflammatory, hormonal, vascular, and structural domains, then a single-mechanism intervention would be expected to help only temporarily and partially. The limited response durations are evidence that the interventions are incomplete.

4. Evidence for Multi-Domain Dysfunction in Joint Pain

4.1 Mitochondrial Function and Metabolic Dysfunction

The concept of metabolic osteoarthritis — joint degeneration driven by systemic metabolic dysfunction rather than mechanical overload alone — has emerged as a major research focus. Insulin resistance indices including the triglyceride-glucose index, triglyceride-glucose-BMI, and visceral adiposity index are significantly associated with knee osteoarthritis in a large population-based analysis from the Korean National Health and Nutrition Examination Survey, even after adjusting for confounding variables (Korean NHANES analysis, 2025). Nearly 47.3% of individuals with diabetes have some form of arthritis, a prevalence that cannot be explained by mechanical factors alone.

The mechanisms connecting insulin resistance to cartilage degeneration operate through multiple converging pathways. Chronically elevated blood sugar produces advanced glycation end products (AGEs) — compounds that cross-link collagen fibers in cartilage, stiffening the extracellular matrix and impairing its ability to absorb mechanical stress. Insulin resistance activates NF-κB, a protein complex that functions as a master switch for inflammatory gene activation, driving production of matrix metalloproteinases (MMPs) — enzymes that degrade the cartilage matrix (Niederberger and Geisslinger, FASEB Journal, 2008). Visceral adipose tissue produces adipokines including leptin and resistin that drive cartilage erosion through direct catabolic effects on chondrocytes. Leptin increases expression of IL-6 and MMP production through an insulin receptor substrate pathway in synovial fibroblasts, directly connecting the metabolic domain to structural cartilage destruction.

The strongest evidence that osteoarthritis is not purely mechanical comes from hand osteoarthritis in obese patients. The hand is not a weight-bearing joint, yet obesity increases the risk of hand osteoarthritis through the same adipokine-mediated inflammatory and metabolic pathways that damage weight-bearing joints. This observation demonstrates that the metabolic consequences of obesity — insulin resistance, chronic inflammation, adipokine production, and AGE accumulation — drive joint degeneration systemically, independent of mechanical load. Weight-bearing joints receive a double insult: mechanical overload plus metabolic destruction.

4.2 The Frozen Shoulder as an Immunometabolic Model

Adhesive capsulitis provides perhaps the clearest clinical example of joint disease as a multi-domain disorder. A 2025 comprehensive review reframed frozen shoulder as a systemic immunometabolic disorder involving estrogen deficiency, thyroid dysfunction, insulin resistance, and endothelial dysfunction rather than an isolated musculoskeletal condition (PMC, 2025). The evidence supporting this reframing is substantial.

Frozen shoulder affects 10–20% of diabetics compared with 2–5% of the general population, representing a two- to four-fold increased risk (Bunker and Anthony, Journal of Bone and Joint Surgery, 1995). Chronic hyperglycemia produces AGEs that accumulate in the shoulder capsule collagen, stiffening connective tissue and promoting fibrosis. Thyroid dysfunction, particularly hypothyroidism, is strongly associated with frozen shoulder through mechanisms including impaired connective tissue maintenance and increased fibrotic signaling. Three-quarters of frozen shoulder patients are female, with the condition peaking during perimenopause and menopause. Estrogen plays critical roles in stimulating bone growth, reducing inflammation, and maintaining connective tissue integrity. When estrogen levels decline, anti-inflammatory, antifibrotic, and antioxidant defenses weaken, predisposing the shoulder capsule to inflammation and fibrosis.

A Duke University study found that postmenopausal women not receiving hormone replacement therapy had 99% greater odds of developing frozen shoulder compared to women receiving estrogen (Wittstein et al., North American Menopause Society, 2023). Elevated levels of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6 have been documented in the synovial fluid and capsular tissue of frozen shoulder patients, confirming an active immune-inflammatory component. Endothelial dysfunction in the shoulder capsule — driven by insulin resistance, inflammation, and estrogen loss — impairs microvascular perfusion, reducing nutrient delivery and waste removal from the capsular tissue. The frozen shoulder is not a mysterious idiopathic condition. It is the predictable outcome of hormonal depletion, metabolic dysfunction, and chronic inflammation converging on a susceptible joint capsule.

4.3 Immune Surveillance and Inflammation

Osteoarthritis is increasingly recognized as an inflammatory disease, not merely a degenerative one. Low-grade synovitis — inflammation of the joint lining — is present in a majority of osteoarthritic joints and correlates with pain severity and disease progression (Berenbaum, Osteoarthritis and Cartilage, 2013). NF-κB activation in chondrocytes and synovial cells drives production of TNF-α, IL-1β, and IL-6, which stimulate MMP expression and cartilage matrix degradation. This is not the intense, acute inflammation of rheumatoid arthritis but rather the chronic, low-grade inflammation characteristic of metabolic syndrome — further connecting the inflammatory and metabolic domains.

Central sensitization — the amplification of pain signals within the spinal cord — contributes to chronic joint pain through glial cell activation and enhanced synaptic transmission (Woolf, Pain, 2011; Watkins and Maier, Physiological Reviews, 2002). Systemic inflammation from any source — gut-derived, adipose-driven, or metabolically generated — feeds this spinal sensitization, explaining why some patients with moderate radiographic osteoarthritis experience severe pain while others with advanced structural damage report minimal symptoms. The disconnect between imaging findings and symptom severity is itself evidence that the biological environment — particularly the inflammatory milieu — determines the pain experience more than the structural pathology alone.

4.4 Neuroendocrine Regulation

Hormonal status profoundly influences joint health. Estrogen maintains cartilage homeostasis through anti-inflammatory effects, stimulation of chondrocyte proliferation, and regulation of subchondral bone turnover. Estrogen decline during perimenopause and menopause accelerates osteoarthritis progression, particularly in the knee and hand, and drives the capsular fibrosis of frozen shoulder. Testosterone deficiency in both men and women reduces anabolic capacity for cartilage and connective tissue maintenance.

Sleep disruption independently predicts chronic pain development and is bidirectionally linked to joint pain (Finan et al., Journal of Pain, 2013; Choy, Nature Reviews Rheumatology, 2015). Growth hormone, released during deep delta sleep, is essential for cartilage repair and proteoglycan synthesis. HPA axis dysregulation from chronic pain and stress produces cortisol abnormalities that impair tissue repair and promote inflammatory disinhibition (Heim et al., Psychoneuroendocrinology, 2000). The deconditioning cycle — joint pain leading to inactivity leading to weight gain leading to worsened insulin resistance leading to accelerated joint destruction — is mediated through the neuroendocrine domain.

4.5 Microbiome and Mucosal Immunity

Gut barrier dysfunction allows bacterial lipopolysaccharide (LPS) to translocate into systemic circulation, activating NF-κB-mediated inflammatory cascades that contribute to synovial inflammation and cartilage degradation (Camilleri, Gut, 2019). The gut-joint axis is an emerging area of research, with gut microbiome composition influencing systemic inflammatory tone and, consequently, joint health. Altered gut microbiome composition has been demonstrated in chronic pain populations (Minerbi et al., Pain, 2019). NSAID use for joint pain damages the gut mucosa, potentially worsening the gut barrier dysfunction that feeds the systemic inflammation driving the osteoarthritis — a therapeutic contradiction in which the treatment for the symptom accelerates the underlying disease.

4.6 Vascular Integrity

Articular cartilage, like the intervertebral disc, is avascular. It depends on diffusion from subchondral bone capillaries and synovial fluid for nutrient delivery and waste removal. Endothelial dysfunction — the impairment of blood vessel lining function that regulates blood flow and nutrient exchange — compromises the subchondral microcirculation, reducing the cartilage’s access to oxygen and growth factors. Insulin resistance, chronic inflammation, and aging all promote endothelial dysfunction through reduced nitric oxide bioavailability. The parallel between the avascular disc and avascular cartilage is direct: as described in the companion low back pain publication (Thomas, Alabama Pain Physicians, 2026), the metabolic and vascular environment determines nutrient delivery to the tissue more than any structural or mechanical factor.

4.7 Structural Domain

Cartilage loss, osteophyte formation, subchondral bone changes, and synovial hypertrophy are the structural hallmarks of osteoarthritis. Capsular thickening and fibrosis define adhesive capsulitis. These structural findings are real and clinically important. However, cellular systems theory proposes that they represent the visible downstream consequences of upstream dysfunction across the metabolic, inflammatory, hormonal, vascular, and mitochondrial domains operating over years or decades. The structural domain is where the biology becomes visible on imaging and palpable on examination. But the structural damage cannot be repaired without addressing the biological environment that produced it.

5. Inter-Domain Cascade Mechanics

5.1 The Metabolic-Inflammatory-Structural Cascade in Osteoarthritis

Insulin resistance drives AGE accumulation in cartilage collagen, stiffening the matrix and impairing nutrient diffusion to chondrocytes. Simultaneously, NF-κB activation (Niederberger and Geisslinger, 2008) upregulates MMPs that degrade the cartilage extracellular matrix. Visceral adipose tissue produces leptin, resistin, and TNF-α that act directly on chondrocytes to promote catabolism and inhibit repair. Endothelial dysfunction from insulin resistance compromises subchondral microcirculation, reducing nutrient delivery to the avascular cartilage. The result is progressive cartilage degeneration driven not by mechanical wear but by metabolic environment. A corticosteroid injection can temporarily suppress local synovial inflammation, but it cannot reverse the AGE accumulation, the adipokine production, the endothelial dysfunction, or the MMP activation. This explains why injections provide weeks of relief followed by recurrence: the biological environment that destroyed the cartilage remains active.

5.2 The Hormonal-Metabolic-Fibrotic Cascade in Frozen Shoulder

Estrogen decline during perimenopause weakens anti-inflammatory and antifibrotic defenses in the shoulder capsule. Simultaneously, the metabolic shifts of menopause — increasing insulin resistance, central adiposity, and inflammatory tone — create the systemic environment that promotes fibrosis. AGEs from insulin resistance stiffen capsular collagen. Thyroid dysfunction, common in perimenopausal women, further impairs connective tissue maintenance and promotes fibrotic remodeling. The HPA axis stress response, often dysregulated during the menopausal transition, elevates cortisol and inflammatory disinhibition. Sleep disruption — common in menopause — reduces growth hormone release needed for capsular repair. The result is a shoulder capsule under simultaneous assault from hormonal withdrawal, metabolic dysfunction, inflammatory activation, and impaired repair capacity. Physical therapy alone cannot override this biology. Corticosteroid injections suppress local inflammation without addressing the hormonal depletion, metabolic dysfunction, or systemic fibrotic signaling that created the condition.

5.3 The Deconditioning-Metabolic-Inflammatory Cascade

Joint pain reduces physical activity. Skeletal muscle is the primary tissue for glucose disposal, and reduced physical activity worsens insulin resistance. Deconditioning reduces mitochondrial density in muscle, further impairing metabolic flexibility. Reduced exercise eliminates the anti-inflammatory effects of physical activity, including endogenous MOTS-c production (Lee et al., Cell Metabolism, 2015). Weight gain from inactivity increases mechanical load on weight-bearing joints while simultaneously increasing adipokine production and systemic inflammation. Pain medications contribute: opioids cause weight gain, sedation, and constipation; beta-blockers impair exercise tolerance; gabapentinoids cause edema and weight gain. The deconditioning cascade is a self-amplifying cycle in which the pain, the metabolic dysfunction, and the inflammatory environment feed each other continuously.

5.4 The Gut-Immune-Joint Cascade

Gut barrier dysfunction (Camilleri, 2019) produces systemic LPS translocation and NF-κB-mediated inflammation that reaches the synovium through systemic circulation. NSAID use for joint pain directly damages the gut mucosa, potentially worsening the barrier dysfunction that feeds the inflammation driving the joint disease. This creates a treatment paradox: the most widely used class of medications for osteoarthritis may accelerate the underlying pathology through gut-mediated inflammatory amplification. Proton pump inhibitors prescribed to protect the stomach from NSAID damage alter the gut microbiome, potentially worsening dysbiosis and its inflammatory consequences.

6. Clinical Scenarios: Individualized Domain Assessment

The following composite clinical scenarios illustrate how cellular systems theory guides individualized assessment and intervention for joint pain. All laboratory values represent plausible clinical findings consistent with the domain dysfunction documented in the cited studies.

6.1 Patient A: Metabolic-Inflammatory Bilateral Knee OA

Presentation: 59-year-old man, BMI 35, with progressive bilateral knee pain over 6 years. Radiographs show moderate bilateral medial compartment osteoarthritis (Kellgren-Lawrence grade 3). Four corticosteroid injections per knee over the past 2 years with diminishing duration of relief (last injection provided 10 days of improvement). Currently taking naproxen 500 mg twice daily and tramadol as needed. Reports fatigue, poor sleep, and inability to exercise due to knee pain. Pain 7/10. Considering bilateral total knee replacement.

Domain Assessment — Laboratory Findings: Fasting insulin 26 µIU/mL (elevated; reference <10), HbA1c 6.3% (prediabetic), HOMA-IR 6.4 (elevated), triglycerides 268 mg/dL, HDL 32 mg/dL. hs-CRP 5.6 mg/L (significantly elevated). Total testosterone 224 ng/dL (low; reference 300–900). DHEA-S low. Morning cortisol 4.8 µg/dL (low; reference 10–20). Vitamin D 17 ng/mL (deficient). Omega-3 index 2.2% (critically low). RBC magnesium low. Leptin elevated.

Domain Interpretation: This patient demonstrates the metabolic-inflammatory-structural cascade. Severe insulin resistance is driving AGE accumulation in cartilage collagen, NF-κB-mediated MMP production, and endothelial dysfunction compromising subchondral microcirculation. Elevated leptin confirms adipokine-mediated cartilage catabolism. Markedly elevated hs-CRP confirms systemic inflammation fed by both insulin resistance and visceral adiposity. Low testosterone and low morning cortisol represent neuroendocrine domain exhaustion, removing anabolic repair capacity. Severely deficient vitamin D and omega-3 impair anti-inflammatory pathways. His chronic NSAID use is damaging the gut mucosa, potentially worsening systemic inflammation through gut barrier compromise. Tramadol is suppressing the HPA axis further. Each corticosteroid injection temporarily suppressed local synovitis but may have accelerated cartilage loss while not addressing any upstream driver. Bilateral TKR would correct the end-stage structural damage but would not address the metabolic environment that would continue to damage other joints and impair surgical outcomes.

Individualized Protocol: Metabolic optimization: anti-inflammatory dietary protocol targeting insulin sensitization, guided by continuous glucose monitoring. Graded aquatic exercise program progressing to land-based Zone 2 training as tolerated. NSAID taper with interventional procedures for acute flares. Testosterone optimization guided by endocrine assessment. Vitamin D repletion to 50–80 ng/mL. Omega-3 repletion to index >8%. Magnesium repletion. MOTS-c (5–10 mg SC three times weekly, morning) targeting AMPK activation and insulin sensitization (Lee et al., Cell Metabolism, 2015). BPC-157 (250–500 µg orally twice daily) for gut barrier support during NSAID taper and nitric oxide restoration (Gwyer et al., Cell and Tissue Research, 2019). GHK-Cu (1–2 mg SC daily) for collagen and glycosaminoglycan stimulation (Pickart and Margolina, BioMed Research International, 2014; Pickart et al., International Journal of Molecular Sciences, 2018). Hyaluronic acid (5 mg SC periarticular weekly for 6 weeks) for joint lubrication. Ipamorelin/CJC-1295 at bedtime for growth hormone restoration. DSIP (100–200 µg SC at bedtime) for deep sleep restoration. Reassessment of metabolic, inflammatory, and hormonal markers at 6 months. Defer surgical decision pending metabolic optimization.

6.2 Patient B: Hormonal-Metabolic Frozen Shoulder

Presentation: 51-year-old woman, BMI 27, perimenopausal (irregular menses for 18 months), with 5-month history of progressive right shoulder pain and stiffness without preceding injury. Diagnosed with adhesive capsulitis based on examination showing severely restricted active and passive external rotation and abduction. Reports night sweats, poor sleep, mood changes, and recent weight gain of 12 pounds. Also reports bilateral hand stiffness in the mornings. Corticosteroid injection provided 3 weeks of modest pain relief. Physical therapy has been painful and minimally effective. Pain 7/10.

Domain Assessment — Laboratory Findings: Fasting insulin 16 µIU/mL (mildly elevated), HbA1c 5.8% (upper normal). Estradiol 28 pg/mL (low perimenopausal). FSH 42 mIU/mL (elevated, confirming perimenopause). TSH 5.2 mIU/L with low-normal free T3 and free T4 (subclinical hypothyroid). Total testosterone 8 ng/dL (low). DHEA-S low. hs-CRP 3.2 mg/L (mildly elevated). Vitamin D 24 ng/mL (suboptimal). HbA1c-derived fructosamine elevated (suggesting AGE accumulation). Omega-3 index 3.4% (low).

Domain Interpretation: This patient demonstrates the hormonal-metabolic-fibrotic cascade. Perimenopausal estrogen decline is removing anti-inflammatory and antifibrotic protection from the shoulder capsule. Subclinical hypothyroidism compounds the fibrotic tendency and impairs connective tissue maintenance. Mild insulin resistance is driving AGE accumulation in capsular collagen and promoting NF-κB activation. Low testosterone and DHEA-S remove anabolic support. The bilateral hand stiffness suggests early systemic connective tissue changes consistent with hormonal and metabolic dysfunction affecting joints beyond the shoulder. This is not an isolated shoulder problem. This is a systemic hormonal-metabolic disorder manifesting at its most vulnerable point — the shoulder capsule. The Duke study showing 99% greater odds of frozen shoulder in women not receiving HRT directly supports this interpretation (Wittstein et al., 2023).

Individualized Protocol: Hormonal optimization: estradiol and progesterone guided by endocrine assessment, targeting perimenopausal symptom relief and connective tissue protection. Thyroid optimization. Testosterone and DHEA optimization. Metabolic optimization targeting insulin sensitization through anti-inflammatory dietary protocol and exercise. Vitamin D repletion. Omega-3 repletion. Physical therapy recalibrated to avoid aggressive stretching during the inflammatory phase. TB-500 (750 µg to 1.5 mg SC twice weekly) for anti-fibrotic tissue remodeling at the capsular level (Malinda et al., Journal of Investigative Dermatology, 1999). GHK-Cu (1–2 mg SC daily) for collagen quality improvement and gene expression modulation toward repair (Pickart and Margolina, 2014). BPC-157 (250–500 µg SC near shoulder and orally) for nitric oxide restoration and tissue repair (Gwyer et al., 2019). MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., 2015). DSIP (100–200 µg SC at bedtime) for sleep restoration during menopausal transition. Selank (250–500 µg SC two to three times daily) for anxiety and HPA axis modulation (Zozulia et al., Zhurnal Nevrologii i Psikhiatrii, 2008). Reassessment of hormonal, metabolic, and inflammatory markers at 12 weeks.

6.3 Patient C: Inflammatory-Vascular-Structural Hip OA

Presentation: 64-year-old man with 4-year history of progressive right hip pain with groin radiation. Radiographs show moderate right hip osteoarthritis with joint space narrowing and marginal osteophytes. Also reports bilateral calf cramping after walking 3 blocks. ABI 0.74 right, 0.78 left (mild PAD). Previous hip corticosteroid injection provided 6 weeks of moderate relief. Currently managing with acetaminophen and topical diclofenac. Pain 6/10. Former smoker (20 pack-years, quit 10 years ago).

Domain Assessment — Laboratory Findings: Fasting insulin 20 µIU/mL (elevated), HbA1c 6.0% (prediabetic). hs-CRP 4.4 mg/L (elevated). Homocysteine 14 µmol/L (elevated). Total testosterone 280 ng/dL (low-normal). Vitamin D 20 ng/mL (deficient). Omega-3 index 2.8% (critically low). Organic acids showing markers consistent with mitochondrial dysfunction and oxidative stress. Heavy metal screen unremarkable.

Domain Interpretation: This patient demonstrates the metabolic-vascular-structural cascade with coexisting hip osteoarthritis and peripheral artery disease sharing the same upstream drivers. Insulin resistance is driving endothelial dysfunction in both the subchondral hip microcirculation and the lower extremity arteries. Elevated homocysteine reflects methylation pathway dysfunction contributing to both vascular damage and cartilage matrix abnormalities. Former smoking history with residual vascular disease confirms endothelial damage. The hip joint, which receives its nutrient supply through subchondral bone capillaries, is particularly vulnerable to microvascular compromise. Metabolic syndrome doubles PAD risk (Garg et al., Hypertension, 2014) and simultaneously accelerates joint degeneration through shared inflammatory and vascular pathology.

Individualized Protocol: Metabolic optimization targeting insulin resistance and endothelial function restoration. Supervised exercise program. Homocysteine reduction through methylfolate and B-vitamin optimization. Vitamin D repletion. Omega-3 repletion. MOTS-c (5–10 mg SC three times weekly) for metabolic optimization (Lee et al., 2015). BPC-157 (250–500 µg SC twice daily near hip and orally) for nitric oxide restoration and endothelial repair (Gwyer et al., 2019). SS-31 (5–10 mg SC daily) for mitochondrial membrane stabilization (Szeto, British Journal of Pharmacology, 2014; Birk et al., JASN, 2013). GHK-Cu (1–2 mg SC daily) for cartilage matrix support (Pickart et al., 2018). NAD+ (IV 250–500 mg 1–2x weekly for loading) for mitochondrial energy substrate. Interventional management (hip injection, possible PAD evaluation for revascularization) for symptomatic control during biological optimization. Reassessment at 6 months.

7. Emerging Peptide Therapeutics: Domain-Targeted Intervention

Peptide therapeutics offer potential for domain-targeted intervention in joint disease. The following peptides have published evidence connecting their mechanisms to biological domains documented as dysfunctional in osteoarthritis and adhesive capsulitis. No randomized controlled trials of these peptides for osteoarthritis as a primary indication have been published; evidence is extrapolated from mechanism-of-action studies and trials in related conditions.

MOTS-c activates AMPK, a master energy-sensing switch, to improve insulin sensitivity, reduce inflammatory cytokines, and promote metabolic homeostasis (Lee et al., Cell Metabolism, 2015). MOTS-c production increases approximately twelve-fold in skeletal muscle during exercise. Its relevance to joint pain is the direct targeting of insulin resistance — the metabolic driver of AGE accumulation, adipokine production, and NF-κB activation documented as central to metabolic osteoarthritis. Subcutaneously at 5–10 mg three times weekly in the morning. Not FDA-approved.

BPC-157 restores nitric oxide production in blood vessel walls, stimulates growth factors, promotes new blood vessel formation to injured areas, and tightens gut epithelial tight junctions (Gwyer et al., Cell and Tissue Research, 2019). Its nitric oxide restoration directly targets the endothelial dysfunction compromising subchondral bone perfusion and joint nutrient delivery. Its gut barrier repair addresses the NSAID-induced mucosal damage that may be worsening systemic inflammation. Orally at 250–500 µg twice daily or subcutaneously near the affected joint. Not FDA-approved.

GHK-Cu stimulates collagen, elastin, and glycosaminoglycan production, and modulates approximately 32% of human gene expression toward repair patterns (Pickart and Margolina, BioMed Research International, 2014; Pickart et al., International Journal of Molecular Sciences, 2018). Glycosaminoglycans are critical components of cartilage extracellular matrix including aggrecan, which provides the compressive resilience that allows joints to absorb mechanical stress. GHK-Cu also activates Nrf2, the master antioxidant switch, reducing oxidative stress in chondrocytes. Subcutaneously at 1–2 mg daily. Not FDA-approved.

TB-500 promotes cell migration to injured tissue and anti-fibrotic tissue remodeling (Malinda et al., Journal of Investigative Dermatology, 1999). Its anti-fibrotic property is particularly relevant to adhesive capsulitis, where capsular fibrosis is the defining pathology. TB-500 promotes proper tissue remodeling rather than scar formation, directly opposing the fibrotic cascade driving frozen shoulder. Subcutaneously at 750 µg to 1.5 mg twice weekly. Not FDA-approved.

Hyaluronic acid (HA) provides cushioning, lubrication, and hydration to joints. HA holds up to 1,000 times its weight in water. Injectable HA delivers the molecule directly to where it is needed rather than relying on oral absorption. Effects can last three to six months per series. HA injections showed more durable benefit than corticosteroid injections in Cochrane comparative analyses and were not associated with accelerated structural progression. Periarticular injection at 5 mg weekly for four to six weeks.

SS-31 (elamipretide) stabilizes the inner mitochondrial membrane by binding cardiolipin, improving bioenergetic efficiency (Szeto, British Journal of Pharmacology, 2014; Birk et al., JASN, 2013). Relevant to osteoarthritis because chondrocytes depend on mitochondrial function for ATP production, matrix synthesis, and resistance to oxidative stress. Clinical trials completed in mitochondrial myopathy (Karaa et al., Neurology, 2018). Subcutaneously at 5–10 mg daily. Not FDA-approved for joint indications.

Peptide protocols are individualized based on domain assessment findings. The clinical scenarios in Section 6 illustrate how peptide selection is directed by laboratory data rather than applied as a standardized protocol. Additional peptides targeting immune regulation, sleep architecture, hormonal restoration, and detoxification may be indicated based on individual assessment.

8. Discussion

The evidence reviewed in this paper supports three propositions. First, joint degeneration in osteoarthritis and adhesive capsulitis involves measurable dysfunction across multiple biological domains, not merely mechanical wear or idiopathic capsular fibrosis. Insulin resistance, adipokine-mediated cartilage catabolism, systemic inflammation, hormonal insufficiency, gut barrier dysfunction, endothelial dysfunction, and oxidative stress have each been independently documented in association with joint disease.

Second, the limited, partial, short-duration response to single-pathway treatments is consistent with a multi-domain disorder. When corticosteroid injections provide weeks of relief and may accelerate structural damage, when NSAIDs manage symptoms but damage the gut lining that feeds systemic inflammation, and when total joint replacement corrects structural damage but leaves the metabolic environment intact, the data are showing that these interventions address only one component of a multi-component problem. Hand osteoarthritis in non-weight-bearing joints of obese patients demonstrates that the metabolic component operates independently of mechanical load. The two- to four-fold increased risk of frozen shoulder in diabetics demonstrates that metabolic and hormonal factors dominate over mechanical factors in capsular pathology.

Third, conventional treatments can actively worsen domains they do not target. NSAIDs damage the gut mucosa, potentially amplifying the inflammatory cascade driving the joint disease. Corticosteroid injections may accelerate cartilage loss. Opioids cause weight gain, hormonal suppression, and deconditioning. Physical therapy for frozen shoulder during the inflammatory phase can worsen capsular inflammation. These destabilizing effects help explain why joint pain is often a progressive condition despite ongoing treatment.

Frozen shoulder serves as the most compelling case study for the multi-domain model because its risk factors — diabetes, thyroid dysfunction, perimenopausal estrogen decline — are all measurable metabolic and hormonal conditions rather than mechanical or traumatic events. The convergence of hormonal withdrawal, metabolic dysfunction, and inflammatory activation at a single joint capsule produces a condition that has historically been called idiopathic precisely because the individual domains were never evaluated together.

Limitations include the narrative methodology, mixed results in studies of metabolic syndrome and osteoarthritis after adjustment for BMI, the preclinical basis of most peptide evidence, and the absence of randomized controlled trials testing multi-domain interventions in joint disease populations. The clinical scenarios are composite illustrations, not case reports from controlled studies. Prospective trials comparing individualized domain-targeted protocols with standard care are needed.

9. Conclusion

Joint pain from osteoarthritis and adhesive capsulitis is treated as a structural-mechanical problem requiring structural intervention, yet the published evidence demonstrates multi-domain biological dysfunction and limited single-pathway treatment durability. The metabolic osteoarthritis model explains why cartilage degenerates, why the frozen shoulder develops, and why conventional treatments provide temporary relief. Adhesive capsulitis in perimenopausal women illustrates the multi-domain principle most clearly: a condition with measurable hormonal, metabolic, thyroid, and inflammatory drivers that has been called idiopathic for decades because no single specialty evaluated all the relevant domains. Cellular systems theory provides a framework for identifying and addressing the metabolic, inflammatory, hormonal, vascular, and microbiome domains driving joint degeneration in each individual patient. Emerging peptide therapeutics targeting metabolic, connective tissue, anti-fibrotic, and mitochondrial pathways warrant prospective clinical investigation in joint disease populations.

Author Information

Ty Thomas, MD, is CEO and Medical Director of Alabama Pain Physicians, a board-certified interventional pain practice in Birmingham and Bessemer, Alabama. Dr. Thomas is board-certified in Physical Medicine and Rehabilitation with additional certification in Venous and Lymphatic Medicine. Alabama Pain Physicians integrates functional laboratory assessment and metabolic optimization with conventional pain management. Contact: 205.332.3160. BamaPain.com.

Disclosures: The author reports no external conflicts of interest relevant to this manuscript. Alabama Pain Physicians offers the laboratory panels and peptide therapeutics described in this review as clinical services. No external funding was received for this work.

References

1. GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050. Lancet Rheumatology. 2023;5(9):e508-e522.

2. Safiri S, Kolahi AA, Smith E, et al. Global, regional and national burden of osteoarthritis 1990–2017. Ann Rheum Dis. 2020;79(6):819-828.

3. Jüni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015;(10):CD005328.

4. Bunker TD, Anthony PP. The pathology of frozen shoulder: a Dupuytren-like disease. J Bone Joint Surg Br. 1995;77(5):677-683.

5. Berenbaum F. Osteoarthritis as an inflammatory disease. Osteoarthritis Cartilage. 2013;21(1):16-21.

6. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.

7. Niederberger E, Geisslinger G. The IKK-NF-κB pathway. FASEB Journal. 2008;22(10):3432-3442.

8. Risk of metabolic abnormalities in osteoarthritis: a new perspective. Bone Research. 2023;11:63.

9. Association between insulin resistance indices and prevalence of knee osteoarthritis. Korean NHANES analysis. 2025.

10. Frozen shoulder as a systemic immunometabolic disorder. PMC. 2025.

11. Wittstein J, et al. Estrogen and frozen shoulder in menopausal women. North American Menopause Society. 2023.

12. Corticosteroid injections associated with higher OA progression on MRI. Radiology. 2024.

13. Woolf CJ. Central sensitization. Pain. 2011;152(3 Suppl):S2-S15.

14. Watkins LR, Maier SF. Immune and glial cells in pathological pain. Physiological Reviews. 2002;82(4):981-1011.

15. Finan PH, Goodin BR, Smith MT. Sleep and pain association. Journal of Pain. 2013;14(12):1539-1552.

16. Choy EH. Sleep in pain and fibromyalgia. Nature Reviews Rheumatology. 2015;11(9):513-520.

17. Heim C, Ehlert U, Hellhammer DH. Hypocortisolism in stress-related disorders. Psychoneuroendocrinology. 2000;25(1):1-35.

18. Camilleri M. Leaky gut: mechanisms and implications. Gut. 2019;68(8):1516-1526.

19. Minerbi A, et al. Altered microbiome in fibromyalgia. Pain. 2019;160(11):2589-2602.

20. Garg PK, Biggs ML, Carnethon M, et al. Metabolic syndrome and risk of incident peripheral artery disease. Hypertension. 2014;63(2):413-419.

21. Lee C, et al. MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015;21(3):443-454.

22. Gwyer D, et al. BPC 157 in musculoskeletal healing. Cell and Tissue Research. 2019;377(2):153-159.

23. Pickart L, Margolina A. GHK and DNA: resetting the genome. BioMed Research International. 2014;2014:151479.

24. Pickart L, et al. GHK-Cu regenerative actions. International Journal of Molecular Sciences. 2018;19(7):1987.

25. Malinda KM, et al. Thymosin beta4 in wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368.

26. Szeto HH. Cardiolipin-protective compound for mitochondrial bioenergetics. British Journal of Pharmacology. 2014;171(8):2029-2050.

27. Birk AV, et al. SS-31 re-energizes mitochondria via cardiolipin. JASN. 2013;24(8):1250-1261.

28. Karaa A, et al. Elamipretide trial in mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.

29. Zozulia AA, et al. Selank in generalized anxiety. Zh Nevrol Psikhiatr. 2008;108(4):38-48.

30. Zhuo Q, Yang W, et al. Metabolic syndrome meets osteoarthritis. Nature Reviews Rheumatology. 2012;8(12):729-737.

31. Courties A, Sellam J, Berenbaum F. Metabolic syndrome-associated osteoarthritis. Curr Opin Rheumatol. 2017;29(2):214-222.

32. Risbud MV, Shapiro IM. Role of cytokines in intervertebral disc degeneration. Nature Reviews Rheumatology. 2014;10(1):44-56.

33. Teraguchi M, et al. Metabolic syndrome and disc degeneration: the Wakayama Spine Study. PLoS One. 2016;11(2):e0147565.

34. Brinjikji W, et al. Imaging features of spinal degeneration in asymptomatic populations. AJNR. 2015;36(4):811-816.

35. Helde-Frankling M, Bjorkhem-Bergman L. Vitamin D in pain management. IJMS. 2017;18(10):2170.

36. Zhai X, et al. Chronic pain and insulin resistance. Journal of Pain. 2016;17:404-413.

37. Fava A, et al. Chronic migraine in women is associated with insulin resistance. Eur J Neurol. 2014;21(2):267-272.

38. Cohen SP, Hooten WM. Advances in diagnosis and management of neck pain. BMJ. 2017;358:j3221.

© 2026 Alabama Pain Physicians. All rights reserved.